Alercell is a young and dynamic company with a team of passionate and dedicated individuals who are committed to making a difference in the fight against cancer. We are constantly striving to improve our products and services to better meet the needs of our customers. Our products are based on the latest technology, and we have an active research and development program to develop new products for even more accurate testing.
Alercell, Inc. aims to streamline the process for testing of infectious diseases and developing cancer testing technology with revolutionary in-vitro testability. We imagine a world where testing detects disease at its earliest stage, so preventative measures can be quickly implemented.
At Alercell, we work to include a broad line of testing products that test for a number of infectious diseases, including COVID-19. Our products have been sold directly to blood banks, hospitals, commercial labs, and testing sites worldwide. Alercell operates within the United States, with manufacturing and storage sites in Europe and Asia, further expanding our worldwide reach and accessibility.
The first Alercell COVID-19 rapid test was shipped from the USA in July 2020. Since then, Alercell has been making waves in the industry with development of new and innovative processes that make tests more accurate, more efficient, and more accessible.